Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Emergent's (EBS) Q2 Earnings and Revenues Miss Estimates
03:37pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
03:40pm, Monday, 01'st Aug 2022 Zacks Investment Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.
The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca
12:10pm, Monday, 01'st Aug 2022 Zacks Investment Research
GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.
Do These 3 New Moneymakers for AstraZeneca Make It a Buy?
12:55pm, Sunday, 31'st Jul 2022 The Motley Fool
Cranking out new medicines is business as usual, but these three could be big earners.
Do These 3 New Moneymakers for AstraZeneca Make It a Buy?
08:55am, Sunday, 31'st Jul 2022
Cranking out new medicines is business as usual, but these three could be big earners.
3 Stocks We Think Could Beat the Market in the Second Half of 2022
10:08am, Saturday, 30'th Jul 2022 The Motley Fool
These stocks share several things in common.
3 Stocks We Think Could Beat the Market in the Second Half of 2022
06:08am, Saturday, 30'th Jul 2022
These stocks share several things in common.
Pharma Stock Roundup: MRK, PFE, SNY Q2 Earnings & Sales Beat, GSK Results Mixed
03:30pm, Friday, 29'th Jul 2022 Zacks Investment Research
GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter results
AstraZeneca (AZN) Beats on Q2 Earnings, Ups Sales Growth View
03:18pm, Friday, 29'th Jul 2022 Zacks Investment Research
AstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.
AstraZeneca Boosts 2022 Sales Outlook, Citing Covid Treatments
09:13am, Friday, 29'th Jul 2022
AstraZeneca raised its full-year sales guidance on strength from its Covid drugs, leading AZN stock to inch higher early Friday. The post AstraZeneca Boosts 2022 Sales Outlook, Citing Covid Treatments
AstraZeneca CFO Sarin on Earnings, Covid, M&A Pipeline
04:05am, Friday, 29'th Jul 2022
AstraZeneca Plc Chief Financial Officer Aradhana Sarin discusses the company's financial results, outlook and strategy. Cambridge, England-based Astra raised its outlook for 2022 revenue after second-
AstraZeneca follows the trend in the sector to upgrade guidance as Covid vaccines sales show resilience
03:13am, Friday, 29'th Jul 2022
AstraZeneca PLC (LSE:AZN) followed its smaller rival GSK PLC (LSE:GSK, NYSE:GSK) by upgrading guidance for the full year after a bumper first half which exceeded expectations. The key driver for the o
AstraZeneca beats Q2 profit and revenue estimates
02:12am, Friday, 29'th Jul 2022
AstraZeneca on Friday topped analyst expectations for second-quarter profit and revenue, helped by higher demand for its cancer medicines.
Merck (MRK) Q2 Earnings & Revenues Top, COVID Drug Helps Sales
05:07pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Merck (MRK) beats on Q2 estimates for earnings and sales. The company continues to see robust growth in COVID drug sales and Keytruda and Gardasil sales.
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
03:40pm, Thursday, 28'th Jul 2022 Zacks Investment Research
On Novavax's (NVAX) second-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
